| 30.6 -4.49 (-12.8%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 41.81 | 1-year : | 48.83 |
| Resists | First : | 35.79 | Second : | 41.81 |
| Pivot price | 27.42  |
|||
| Supports | First : | 27.27 | Second : | 22.01 |
| MAs | MA(5) : | 30.4 |
MA(20) : | 26.91 |
| MA(100) : | 26.72 |
MA(250) : | 17.29 |
|
| MACD | MACD : | 0.7 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 80 |
D(3) : | 74.8 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 35.79 | Low : | 4.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FBRX ] has closed below upper band by 23.9%. Bollinger Bands are 41.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 35.57 - 35.75 | 35.75 - 35.89 |
| Low: | 29.03 - 29.19 | 29.19 - 29.32 |
| Close: | 30.34 - 30.62 | 30.62 - 30.83 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Fri, 10 Apr 2026
Forte Biosciences: 2026 Is Major Inflection Point For FB102 (NASDAQ:FBRX) - Seeking Alpha
Fri, 10 Apr 2026
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts - Seeking Alpha
Thu, 09 Apr 2026
Forte Biosciences Boosts Market Position with $150M Public Offering - timothysykes.com
Thu, 09 Apr 2026
Forte Biosciences (NASDAQ: FBRX) registers 5.71M shares at $26.27 - Stock Titan
Thu, 09 Apr 2026
Brookline Capital Markets Cuts Forte Biosciences FY2026 Earnings Forecast - National Today
Thu, 09 Apr 2026
Forte Biosciences Prices $150 Million Public Offering - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 100.1 (%) |
| Shares Short | 727 (K) |
| Shares Short P.Month | 782 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.1 % |
| Return on Equity (ttm) | -110.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -382.5 |
| PEG Ratio | 0 |
| Price to Book value | 6.48 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|